Hauptseite > Publikationsdatenbank > P01.014 Spatial correlation of FET uptake and MRI contrast enhancement in newly diagnosed glioblastoma patients prior to treatment > print

001     908207
005     20220621190117.0
024 7 _ |a 10.1093/neuonc/noy139.056
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
037 _ _ |a FZJ-2022-02458
082 _ _ |a 610
100 1 _ |a Lohmann, P.
|0 P:(DE-Juel1)145110
|b 0
|e Corresponding author
|u fzj
245 _ _ |a P01.014 Spatial correlation of FET uptake and MRI contrast enhancement in newly diagnosed glioblastoma patients prior to treatment
260 _ _ |c 2018
336 7 _ |a Text
|2 DataCite
336 7 _ |a Communication
|b comm
|m comm
|0 PUB:(DE-HGF)4
|s 1655804421_16933
|2 PUB:(DE-HGF)
336 7 _ |a MISC
|2 BibTeX
336 7 _ |a OTHER
|2 ORCID
336 7 _ |a Other
|2 DINI
336 7 _ |a Personal Communication
|0 4
|2 EndNote
520 _ _ |a BackgroundA complete glioma resection is known to prolong survival. Contrast enhancement (CE) in MRI is usually the target for resection but the solid tumor mass may extend beyond the area of CE. It has been demonstrated that amino acid PET can detect tumor parts showing no CE in MRI. We systematically investigated the volumetric correlation of amino acid uptake with PET and CE in MRI in newly diagnosed and untreated glioblastoma patients.Material and MethodsPreoperatively, 26 patients were examined by O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET and contrast-enhanced MRI. Enhancing tumor areas on MRI were manually segmented on each transverse section and the sum of the areas was multiplied by the slice thickness to obtain contrast-enhancing volumes. The calculation of FET PET tumor volumes was based on an auto-contouring process using a tumor-to-brain ratio of 1.6 or more. For volumetric comparison, the Dice and Jaccard spatial similarity coefficients (DSC; JSC) and the percentage of overlapping volumes (OV) were calculated. Postoperatively, a glioblastoma was confirmed neuropathologically in all patients.ResultsFET PET tumor volumes were significantly larger than contrast-enhancing volumes (26.7 ± 13.4 mL vs. 15.1 ± 11.5 mL; P=0.002). The spatial similarity between FET PET and CE was poor (mean DSC, 0.44 ± 0.18; mean JSC, 0.30 ± 0.14). Additionally, approximately one quarter of patients (n=7) showed a low spatial overlap (mean OV, 36 ± 18%).ConclusionThe present data suggest that the metabolic tumor volume as detected by FET PET is substantially underestimated by CE. Information derived from both imaging modalities should be integrated for the routine management of patients with newly diagnosed glioblastoma.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Stavrinou, P.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Lipke, K.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Bauer, E. K.
|0 P:(DE-Juel1)159312
|b 3
|u fzj
700 1 _ |a Ceccon, G.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Werner, J.
|b 5
700 1 _ |a Fink, G. R.
|0 P:(DE-Juel1)131720
|b 6
|u fzj
700 1 _ |a Shah, N. J.
|0 P:(DE-Juel1)131794
|b 7
|u fzj
700 1 _ |a Langen, K.
|0 P:(DE-Juel1)131777
|b 8
|u fzj
700 1 _ |a Galldiks, N.
|0 P:(DE-Juel1)143792
|b 9
|u fzj
773 _ _ |a 10.1093/neuonc/noy139.056
|0 PERI:(DE-600)2094060-9
|y 2018
|g Vol. 20, no. suppl_3, p. iii231 - iii231
|x 1523-5866
909 C O |o oai:juser.fz-juelich.de:908207
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)145110
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)159312
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131720
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)131777
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 0
920 1 _ |0 I:(DE-Juel1)INM-11-20170113
|k INM-11
|l Jara-Institut Quantum Information
|x 1
920 1 _ |0 I:(DE-Juel1)VDB1046
|k JARA-BRAIN
|l Jülich-Aachen Research Alliance - Translational Brain Medicine
|x 2
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 3
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 4
980 _ _ |a comm
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-11-20170113
980 _ _ |a I:(DE-Juel1)VDB1046
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21